In addition to its role as a prognostic marker, the overexpression of the PVR gene and its serum levels in MM points to its implication in immune evasion and tumor aggressiveness by interacting with immune checkpoint receptors such as TIGIT and CD96. This evidence concerns the gene CD96 and Miyoshi myopathy.